{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:35:52Z","timestamp":1791041752511,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>This study was to investigate the association between oral anticoagulant use and 28-day mortality and in-hospital mortality in patients with acute respiratory distress syndrome (ARDS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 1754 ARDS patients were identified in database from 2008 to 2022 in this cohort study. Univariable and multivariable cox regression models were applied to assess the associations of oral anticoagulant use with the risk of 28-day mortality and in-hospital mortality. Propensity score matching (PSM) was performed in ARDS patients according to whether they were taking oral anticoagulants or not to control potential bias. Subgroup analysis was performed according to severity of ARDS (mild, moderate, and severe), and comorbidities (atrial fibrillation, sepsis, and AKI). Hazards ratio (HR) and respective confidence interval (CI) were presented.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 7758 patients not receiving oral anticoagulant and 905 patients receiving oral anticoagulant. The reduced risk of 28-day mortality in ARDS patients was identified in those undergoing oral anticoagulant use (HR = 0.32, 95%CI: 0.24\u20130.44). Oral anticoagulant use was associated with reduced risk of in-hospital mortality (HR = 0.27, 95%CI: 0.20\u20130.37). After adjusting for the respective confounding factors, the associations of Warfarin with decreased risk of 28-day and in-hospital mortality were not significant (<jats:italic>P<\/jats:italic> &amp;gt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Oral anticoagulant was related to decreased risk of 28-day\/in-hospital mortality in patients with ARDS. Warfarin and novel oral anticoagulants showed no significant difference on 28-day\/in-hospital mortality in patients with ARDS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1565312","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:49:41Z","timestamp":1747208981000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Roles of oral anticoagulant use on the risk of 28-day mortality and in-hospital mortality in patients with acute respiratory distress syndrome"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiayang","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"B1","unstructured":"COVID-19-Hematology.org sgouoaipw\n          \n          \n          2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.amjsurg.2015.07.005","article-title":"Novel oral anticoagulants vs warfarin for the management of postoperative atrial fibrillation: clinical outcomes and cost analysis","volume":"210","author":"Anderson","year":"2015","journal-title":"Am. J. Surg."},{"key":"B3","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2016.0291","article-title":"Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries","volume":"315","author":"Bellani","year":"2016","journal-title":"Jama"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e069333","DOI":"10.1136\/bmjopen-2022-069333","article-title":"Survival benefits of oral anticoagulation therapy in acute kidney injury patients with atrial fibrillation: a retrospective study from the mimic-iv database","volume":"13","author":"Bo","year":"2023","journal-title":"BMJ open"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/s0140-6736(22)01485-4","article-title":"Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes","volume":"400","author":"Bos","year":"2022","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.21037\/atm.2018.01.08","article-title":"Anticoagulant therapy in acute respiratory distress syndrome","volume":"6","author":"Camprub\u00ed-Rimblas","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.51893\/2020.2.pov2","article-title":"Microvascular covid-19 lung vessels obstructive thromboinflammatory syndrome (microclots): an atypical acute respiratory distress syndrome working hypothesis","volume":"22","author":"Ciceri","year":"2020","journal-title":"Crit. care Resusc. J. Australas. Acad. Crit. Care Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ijcard.2020.12.024","article-title":"Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: a population-based propensity score matched study","volume":"329","author":"Denas","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/s2213-2600(20)30470-7","article-title":"Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"9","author":"Dixon","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.4103\/njcp.njcp_125_22","article-title":"Bleeding events in the emergency department with warfarin versus novel oral anticoagulants: a five-year analysis","volume":"25","author":"Dogan","year":"2022","journal-title":"Niger. J. Clin. Pract."},{"key":"B11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/joim.13205","article-title":"Direct oral anticoagulant use and risk of severe COVID-19","volume":"289","author":"Flam","year":"2021","journal-title":"J. Intern. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.thromres.2020.03.023","article-title":"The significance of disseminated intravascular coagulation on multiple organ dysfunction during the early stage of acute respiratory distress syndrome","volume":"191","author":"Gando","year":"2020","journal-title":"Thrombosis Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.thromres.2019.04.025","article-title":"Role of disseminated intravascular coagulation in severe sepsis","volume":"178","author":"Gando","year":"2019","journal-title":"Thrombosis Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1322045","DOI":"10.3389\/fcvm.2024.1322045","article-title":"Oral anticoagulants increased 30-day survival in sepsis patients complicated with atrial fibrillation: a retrospective analysis from mimic-iv database","volume":"11","author":"Ge","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"key":"B15","first-page":"1009","article-title":"The acute respiratory distress syndrome: mechanisms and perspective therapeutic approaches","volume":"2","author":"Gonzales","year":"2015","journal-title":"Austin J. Vasc. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2466-12-43","article-title":"Early intravenous unfractionated heparin and outcome in acute lung injury and acute respiratory distress syndrome: a retrospective propensity matched cohort study","volume":"12","author":"Hofstra","year":"2012","journal-title":"BMC Pulm. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41597-022-01899-x","article-title":"Mimic-iv, a freely accessible electronic health record dataset","volume":"10","author":"Johnson","year":"2023","journal-title":"Sci. Data"},{"key":"B18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.amjms.2024.04.012","article-title":"Association of coagulation function with the risk of in-hospital mortality in patients with severe acute respiratory distress syndrome","volume":"368","author":"Li","year":"2024","journal-title":"Am. J. Med. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/s0140-6736(21)00439-6","article-title":"Acute respiratory distress syndrome","volume":"398","author":"Meyer","year":"2021","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1600-0609.2009.01238.x","article-title":"A review of pulmonary coagulopathy in acute lung injury, acute respiratory distress syndrome and pneumonia","volume":"82","author":"Nieuwenhuizen","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1001\/jama.2012.5669","article-title":"Acute respiratory distress syndrome: the Berlin definition","volume":"307","author":"Ranieri","year":"2012","journal-title":"Jama"},{"key":"B22","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10557-021-07194-y","article-title":"Chronic oral anticoagulation and clinical outcome in hospitalized COVID-19 patients","volume":"36","author":"Russo","year":"2022","journal-title":"Cardiovasc. Drugs Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10496","DOI":"10.1016\/j.phrs.2020.104965","article-title":"Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with covid-19: a multicenter observational study","volume":"159","author":"Russo","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/thorax.2003.013888","article-title":"Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia","volume":"59","author":"Schultz","year":"2004","journal-title":"Thorax"},{"key":"B25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.thromres.2020.11.017","article-title":"Pulmonary embolism in covid-19 patients: prevalence, predictors and clinical outcome","volume":"198","author":"Scudiero","year":"2021","journal-title":"Thrombosis Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s00134-018-5480-6","article-title":"Acute respiratory distress syndrome (ards) phenotyping","volume":"45","author":"Shankar-Hari","year":"2019","journal-title":"Intensive care Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/shk.0000000000002145","article-title":"The critical role of the histone modification enzyme Setdb2 in the pathogenesis of acute respiratory distress syndrome","volume":"60","author":"Sonobe","year":"2023","journal-title":"Shock (Augusta, Ga)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thrombosis Haemostasis JTH"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/jth.14810","article-title":"Isth interim guidance on recognition and management of coagulopathy in covid-19","volume":"18","author":"Thachil","year":"2020","journal-title":"J. Thrombosis Haemostasis JTH"},{"key":"B30","doi-asserted-by":"publisher","first-page":"R70","DOI":"10.1186\/cc11325","article-title":"Nebulized anticoagulants for acute lung injury - a systematic review of preclinical and clinical investigations","volume":"16","author":"Tuinman","year":"2012","journal-title":"Crit. care"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1111\/bcp.15253","article-title":"Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID-19 Requiring invasive ventilation Meta-Trial (CHARTER-MT): protocol and statistical analysis plan for an investigator-initiated international meta-trial of prospective randomised clinical studies","volume":"88","author":"van Haren","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"440","DOI":"10.5114\/ait.2021.110608","article-title":"Use of direct oral anticoagulants in icu patients. Part Ii - clinical evidence","volume":"53","author":"Wahab","year":"2021","journal-title":"Anaesthesiol. Intensive Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1056\/nejm200005043421806","article-title":"The acute respiratory distress syndrome","volume":"342","author":"Ware","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1055\/s-0040-1720962","article-title":"Safety and efficacy of apixaban for therapeutic anticoagulation in critically ill ICU patients with severe COVID-19 respiratory disease","volume":"4","author":"Wenzler","year":"2020","journal-title":"TH Open"},{"key":"B35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40560-024-00723-5","article-title":"Exploring the therapeutic role of early heparin administration in ards management: a mimic-iv database analysis","volume":"12","author":"Xiao","year":"2024","journal-title":"J. Intensive Care"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1565312\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:49:45Z","timestamp":1747208985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1565312\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":35,"alternative-id":["10.3389\/fphar.2025.1565312"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1565312","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"article-number":"1565312"}}